Refractory ITP: revisiting definitions, diagnostics, and management paradigms Available to Purchase

2.

McMillan

R

,

Durette

C

.

Long-term outcomes in adults with chronic ITP after splenectomy failure

.

Blood

.

2004

;

104

(

4

):

956

-

960

.

3.

Moulis

G

,

Rueter

M

,

Duvivier

A

, et al;

CARMEN-France Investigators Group

.

Difficult-to-treat primary immune thrombocytopenia in adults: prevalence and burden. Results from the CARMEN-France registry

.

Br J Haematol

.

2024

;

204

(

4

):

1476

-

1482

.

4.

Rodeghiero

F

,

Stasi

R

,

Gernsheimer

T

, et al.

Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group

.

Blood

.

2009

;

113

(

11

):

2386

-

2393

.

5.

Arnold

DM

,

Clerici

B

,

Ilicheva

E

,

Ghanima

W

.

Refractory immune thrombocytopenia in adults: towards a new definition

.

Br J Haematol

.

2023

;

203

(

1

):

23

-

27

.

6.

Nakano

TA

,

Grimes

AB

,

Klaassen

RJ

, et al.

What is in a name: defining pediatric refractory ITP

.

Blood Adv

.

2024

;

8

(

19

):

5112

-

5117

.

7.

Vianelli

N

,

Auteri

G

,

Buccisano

F

, et al.

Refractory primary immune thrombocytopenia (ITP): current clinical challenges and therapeutic perspectives

.

Ann Hematol

.

2022

;

101

(

5

):

963

-

978

.

8.

Miltiadous

O

,

Hou

M

,

Bussel

JB

.

Identifying and treating refractory ITP: difficulty in diagnosis and role of combination treatment

.

Blood

.

2020

;

135

(

7

):

472

-

490

.

9.

Cuker

A

,

Neunert

CE

.

How I treat refractory immune thrombocytopenia

.

Blood

.

2016

;

128

(

12

):

1547

-

1554

.

10.

Ghanima

W

,

Cuker

A

,

Michel

M

.

Insights on treatment of adult ITP: algorithm for management and role of multimodal therapy

.

Hematology Am Soc Hematol Educ Program

.

2024

;

2024

(

1

):

678

-

684

.

11.

Cooper

N

,

Morrison

MA

,

Vladescu

C

, et al.

Identification of occult cerebral microbleeds in adults with immune thrombocytopenia

.

Blood

.

2020

;

136

(

25

):

2875

-

2880

.

12.

Cooper

N

,

Kruse

A

,

Kruse

C

, et al.

Immune thrombocytopenia (ITP) World Impact Survey (iWISh): patient and physician perceptions of diagnosis, signs and symptoms, and treatment

.

Am J Hematol

.

2021

;

96

(

2

):

188

-

198

.

13.

Kuter

DJ

,

Ghanima

W

,

Cooper

N

, et al.

Safety and efficacy of rilzabrutinib vs placebo in adults with immune thrombocytopenia: the phase 3 LUNA3 study

.

Blood

.

2025

;

145

(

24

):

2914

-

2926

.

14.

Cines

DB

,

Bussel

JB

,

Liebman

HA

,

Luning Prak

ET

.

The ITP syndrome: pathogenic and clinical diversity

.

Blood

.

2009

;

113

(

26

):

6511

-

6521

.

15.

Roeser

A

,

Lazarus

AH

,

Mahévas

M

.

B cells and antibodies in refractory immune thrombocytopenia

.

Br J Haematol

.

2023

;

203

(

1

):

43

-

53

.

16.

Yazdanbakhsh

K

,

Provan

D

,

Semple

JW

.

The role of T cells and myeloid-derived suppressor cells in refractory immune thrombocytopenia

.

Br J Haematol

.

2023

;

203

(

1

):

54

-

61

.

17.

Åkesson

A

,

Bussel

JB

,

Martin

M

, et al.

Complement activation negatively affects the platelet response to thrombopoietin receptor agonists in patients with immune thrombocytopenia: a prospective cohort study

.

Platelets

.

2023

;

34

(

1

):

2159019

.

18.

Broome

CM

,

McDonald

V

,

Miyakawa

Y

, et al;

ADVANCE Investigator Study Group

.

Efficacy and safety of the neonatal Fc receptor inhibitor efgartigimod in adults with primary immune thrombocytopenia (ADVANCE IV): a multicentre, randomised, placebo-controlled, phase 3 trial

.

Lancet

.

2023

;

402

(

10413

):

1648

-

1659

.

19.

Strüßmann

T

,

Heinz

J

,

Wäsch

R

, et al.

Long-term complete remissions of refractory severe idiopathic immune thrombocytopenia treated with daratumumab: a case series

.

Br J Haematol

.

2024

;

205

(

4

):

1618

-

1621

.

20.

Khodadadi

L

,

Cheng

Q

,

Alexander

T

, et al.

Bortezomib plus continuous B cell depletion results in sustained plasma cell depletion and amelioration of lupus nephritis in NZB/W F1 mice

.

PLoS One

.

2015

;

10

(

8

):

e0135081

.

21.

Colunga-Pedraza

PR

,

Peña-Lozano

SP

,

Sánchez-Rendón

E

, et al.

Oseltamivir as rescue therapy for persistent, chronic, or refractory immune thrombocytopenia: a case series and review of the literature

.

J Thromb Thrombolysis

.

2022

;

54

(

2

):

360

-

366

.

22.

Sun

L

,

Wang

J

,

Shao

L

, et al.

Dexamethasone plus oseltamivir versus dexamethasone in treatment-naive primary immune thrombocytopenia: a multicentre, randomised, open-label, phase 2 trial

.

Lancet Haematol

.

2021

;

8

(

4

):

e289

-

e298

.

23.

Bussel

J

,

Arnold

DM

,

Grossbard

E

, et al.

Fostamatinib for the treatment of adult persistent and chronic immune thrombocytopenia: results of two phase 3, randomized, placebo-controlled trials

.

Am J Hematol

.

2018

;

93

(

7

):

921

-

930

.

24.

Malik

A

,

Sayed

AA

,

Han

P

, et al.

The role of CD8+ T-cell clones in immune thrombocytopenia

.

Blood

.

2023

;

141

(

20

):

2417

-

2429

.

25.

Broome

CM

,

Röth

A

,

Kuter

DJ

, et al.

Safety and efficacy of classical complement pathway inhibition with sutimlimab in chronic immune thrombocytopenia

.

Blood Adv

.

2023

;

7

(

6

):

987

-

996

.

26.

Jiang

D

,

Rosenlind

K

,

Baxter

S

, et al.

Evaluating the prevalence of inborn errors of immunity in adults with chronic immune thrombocytopenia or Evans syndrome

.

Blood Adv

.

2023

;

7

(

23

):

7202

-

7208

.

27.

Joshi

N

,

Lango-Allen

H

,

Downes

K

, et al.

The role of genetic sequencing in the diagnostic workup for chronic immune thrombocytopenia

.

Blood Adv

.

2025

;

9

(

7

):

1497

-

1507

.

28.

Fattizzo

B

,

Marchetti

A

,

Bosi

A

, et al.

Clonal hematopoiesis in patients with autoimmune thrombocytopenia: an international multicenter study

.

Blood Adv

.

2025

;

9

(

3

):

488

-

495

.

29.

Shao

L

,

Boothby

A

,

Bailey

SL

, et al.

T-cell transcriptomic signatures in adults with primary untreated immune thrombocytopenia segregate by age, revealing distinct druggable pathways

.

Blood

.

2024

;

144

(suppl

1

):

124

.

30.

Rao

VK

,

Pittaluga

S

,

Uzel

G

.

Beyond FAScinating: advances in diagnosis and management of autoimmune lymphoproliferative syndrome and activated PI3 kinase δ syndrome

.

Hematology Am Soc Hematol Educ Program

.

2024

;

2024

(

1

):

126

-

136

.

31.

Alan

TN

,

Paquita

N

.

Inherited thrombocytopenias: history, advances and perspectives

.

Haematologica

.

2020

;

105

(

8

):

2004

-

2019

.

32.

Bonadies

N

,

Rovó

A

,

Porret

N

,

Bacher

U

.

When should we think of myelodysplasia or bone marrow failure in a thrombocytopenic patient? A practical approach to diagnosis

.

J Clin Med

.

2021

;

10

(

5

):

1026

.

33.

Provan

D

,

Arnold

DM

,

Bussel

JB

, et al.

Updated international consensus report on the investigation and management of primary immune thrombocytopenia

.

Blood Adv

.

2019

;

3

(

22

):

3780

-

3817

.

34.

Neunert

C

,

Lim

W

,

Crowther

M

, et al.

The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia

.

Blood

.

2011

;

117

(

16

):

4190

-

4207

.

35.

Ali

I

,

Graham

C

,

Dempsey-Hibbert

NC

.

Immature platelet fraction as a useful marker in the etiological determination of thrombocytopenia

.

Exp Hematol

.

2019

;

78

:

56

-

61

.

36.

Vitale

C

,

Salvetti

C

,

Griggio

V

, et al.

Preexisting and treatment-emergent autoimmune cytopenias in patients with CLL treated with targeted drugs

.

Blood

.

2021

;

137

(

25

):

3507

-

3517

.

37.

Moulis

G

,

Aladjidi

N

,

Godeau

B

.

Clinical significance of antinuclear antibodies in primary immune thrombocytopenia

.

Br J Haematol

.

2023

;

203

(

1

):

131

-

135

.

38.

Taparia

K

,

Wall

E

,

Arnold

DM

,

Sun

HL

.

Frequency and utility of bone marrow examination in relapsed/refractory immune thrombocytopenia

.

J Thromb Haemost

.

2022

;

20

(

9

):

2119

-

2126

.

39.

Moulis

G

,

Germain

J

,

Comont

T

, et al;

CARMEN Investigators Group

.

Newly diagnosed immune thrombocytopenia adults: clinical epidemiology, exposure to treatments, and evolution. Results of the CARMEN multicenter prospective cohort

.

Am J Hematol

.

2017

;

92

(

6

):

493

-

500

.

40.

Arnold

DM

,

Nazy

I

,

Clare

R

, et al.

Misdiagnosis of primary immune thrombocytopenia and frequency of bleeding: lessons from the McMaster ITP Registry

.

Blood Adv

.

2017

;

1

(

25

):

2414

-

2420

.

41.

Moulis

G

,

Palmaro

A

,

Montastruc

JL

,

Godeau

B

,

Lapeyre-Mestre

M

,

Sailler

L

.

Epidemiology of incident immune thrombocytopenia: a nationwide population-based study in France

.

Blood

.

2014

;

124

(

22

):

3308

-

3315

.

42.

Bradbury

CA

,

Pell

J

,

Hill

Q

, et al.

Mycophenolate mofetil for first-line treatment of immune thrombocytopenia

.

N Engl J Med

.

2021

;

385

(

10

):

885

-

895

.

43.

Gudbrandsdottir

S

,

Birgens

HS

,

Frederiksen

H

, et al.

Rituximab and dexamethasone vs dexamethasone monotherapy in newly diagnosed patients with primary immune thrombocytopenia

.

Blood

.

2013

;

121

(

11

):

1976

-

1981

.

44.

An

ZY

,

Wu

YJ

,

He

Y

, et al.

Tacrolimus plus high-dose dexamethasone versus high-dose dexamethasone alone as first-line treatment for adult immune thrombocytopenia: the phase 2, open label, randomized trial (TARGET 020)

.

Blood

.

2021

;

138

(suppl

1

):

13

.

45.

Zhang

L

,

Zhang

M

,

Du

X

,

Cheng

Y

,

Cheng

G

.

Safety and efficacy of eltrombopag plus pulsed dexamethasone as first-line therapy for immune thrombocytopenia

.

Br J Haematol

.

2020

;

189

(

2

):

369

-

378

.

46.

Huang

QS

,

Liu

Y

,

Wang

JB

, et al.

All-trans retinoic acid plus high-dose dexamethasone as first-line treatment for patients with newly diagnosed immune thrombocytopenia: a multicentre, open-label, randomised, controlled, phase 2 trial

.

Lancet Haematol

.

2021

;

8

(

10

):

e688

-

e699

.

47.

Al-Samkari

H

,

Kuter

DJ

.

Thrombopoietin level predicts response to treatment with eltrombopag and romiplostim in immune thrombocytopenia

.

Am J Hematol

.

2018

;

93

(

12

):

1501

-

1508

.

48.

Al-Samkari

H

,

Jiang

D

,

Gernsheimer

T

, et al.

Adults with immune thrombocytopenia who switched to avatrombopag following prior treatment with eltrombopag or romiplostim: a multicentre US study

.

Br J Haematol

.

2022

;

197

(

3

):

359

-

366

.

49.

Deng

J

,

Hu

H

,

Huang

F

, et al.

Comparative efficacy and safety of thrombopoietin receptor agonists in adults with thrombocytopenia: a systematic review and network meta-analysis of randomized controlled trial

.

Front Pharmacol

.

2021

;

12

:

704093

.

50.

Al-Samkari

H

,

Kuter

DJ

.

Relative potency of the thrombopoietin receptor agonists eltrombopag, avatrombopag and romiplostim in a patient with chronic immune thrombocytopenia

.

Br J Haematol

.

2018

;

183

(

2

):

168

.

51.

Zhang

J

,

Wang

Z

,

Chen

H

,

Lu

X

.

Combination of two target agonists of the thrombopoietin and thrombopoietin receptor in the treatment of elderly patients with refractory immune thrombocytopenia

.

Cancer Pathog Ther

.

2023

;

1

(

2

):

154

-

156

.

52.

Lucchini

E

,

Zaja

F

,

Bussel

J

.

Rituximab in the treatment of immune thrombocytopenia: what is the role of this agent in 2019?

Haematologica

.

2019

;

104

(

6

):

1124

-

1135

.

53.

Bride

KL

,

Vincent

T

,

Smith-Whitley

K

, et al.

Sirolimus is effective in relapsed/refractory autoimmune cytopenias: results of a prospective multi- institutional trial

.

Blood

.

2016

;

127

(

1

):

17

-

28

.

54.

Mendoza

A

,

Álvarez-Román

MT

,

Monzón-Manzano

E

, et al.

Study of platelet kinetics in immune thrombocytopenia to predict splenectomy response

.

Br J Haematol

.

2024

;

204

(

1

):

315

-

323

.

55.

Seidel

MG

.

Treatment of immune-mediated cytopenias in patients with primary immunodeficiencies and immune regulatory disorders (PIRDs)

.

Hematology Am Soc Hematol Educ Program

.

2020

;

2020

(

1

):

673

-

679

.

56.

Rao

VK

,

Webster

S

,

Dalm

VASH

, et al.

Effective “activated PI3Kδ syndrome”– targeted therapy with the PI3Kδ inhibitor leniolisib

.

Blood

.

2017

;

130

(

21

):

2307

-

2316

.

57.

Nguyen

TH

,

Chandrakasan

S

.

Biomarkers of immune dysregulation and what they tell us: gene sequencing is not the answer to every question

.

Immunol Allergy Clin North Am

.

2025

;

45

(

2

):

173

-

188

.

58.

Xu

Y

,

Chen

Y

,

Zhang

L

.

Review: advances in the pathogenesis and treatment of immune thrombocytopenia associated with viral hepatitis

.

Glob Med Genet

.

2023

;

10

(

3

):

229

-

233

.

59.

Tajiri

K

,

Okada

K

,

Ito

H

, et al.

Long term changes in thrombocytopenia and leucopenia after HCV eradication with direct-acting antivirals

.

BMC Gastroenterol

.

2023

;

23

(

1

):

182

.

60.

Izak

M

,

Bussel

JB

.

Management of thrombocytopenia

.

F1000Prime Rep

.

2014

;

6

:

45

.

61.

Jalink

M

,

Jacobs

CF

,

Khwaja

J

, et al.

Daratumumab monotherapy in refractory warm autoimmune hemolytic anemia and cold agglutinin disease

.

Blood Adv

.

2024

;

8

(

11

):

2622

-

2634

.

62.

Rao

A

,

Kelly

M

,

Musselman

M

, et al.

Safety, efficacy, and immune reconstitution after rituximab therapy in pediatric patients with chronic or refractory hematologic autoimmune cytopenias

.

Pediatr Blood Cancer

.

2008

;

50

(

4

):

822

-

825

.

63.

Rao

VK

,

Price

S

,

Perkins

K

, et al.

Use of rituximab for refractory cytopenias associated with autoimmune lymphoproliferative syndrome (ALPS)

.

Pediatr Blood Cancer

.

2009

;

52

(

7

):

847

-

852

.

64.

Parodi

E

,

Rivetti

E

,

Amendola

G

, et al.

Long-term follow-up analysis after rituximab therapy in children with refractory symptomatic ITP: identification of factors predictive of a sustained response

.

Br J Haematol

.

2009

;

144

(

4

):

552

-

558

.

65.

Grace

RF

,

Bennett

CM

,

Ritchey

AK

, et al.

Response to steroids predicts response to rituximab in pediatric chronic immune thrombocytopenia

.

Pediatr Blood Cancer

.

2012

;

58

(

2

):

221

-

225

.

66.

Pasquet

M

,

Aladjidi

N

,

Guiton

C

, et al.

Romiplostim in children with chronic immune thrombocytopenia (ITP): the French experience

.

Br J Haematol

.

2014

;

164

(

2

):

266

-

271

.

67.

Matsubara

K

,

Takahashi

Y

,

Hayakawa

A

, et al.

Long-term follow-up of children with refractory immune thrombocytopenia treated with rituximab

.

Int J Hematol

.

2014

;

99

(

4

):

429

-

436

.

68.

Evim

MS

,

Baytan

B

,

Güneş

AM

.

Childhood Immune Thrombocytopenia: Long-term Follow-up Data Evaluated by the Criteria of the International Working Group on Immune Thrombocytopenic Purpura

.

Turk J Haematol

.

2014

;

31

(

1

):

32

-

39

.

69.

Adly

AA

,

Ragab

IA

,

Ismail

EA

,

Farahat

MM

.

Evaluation of the immature platelet fraction in the diagnosis and prognosis of childhood immune thrombocytopenia

.

Platelets

.

2015

;

26

(

7

):

645

-

650

.

70.

Ay

Y

,

Karapinar

TH

,

Oymak

Y

, et al.

Retrospective analysis of rituximab therapy and splenectomy in childhood chronic and refractory immune thrombocytopenic purpura

.

Blood Coagul Fibrinolysis

.

2016

;

27

(

4

):

431

-

435

.

71.

Khera

S

,

Pramanik

SK

,

Yanamandra

U

,

Mishra

K

,

Kapoor

R

,

Das

S

.

Dapsone: An Old but Effective Therapy in Pediatric Refractory Immune Thrombocytopenia

.

Indian J Hematol Blood Transfus

.

2020

;

36

(

4

):

690

-

694

.

72.

Ibrahim

L

,

Dong

SX

,

O’Hearn

K

, et al.

Pediatric refractory immune thrombocytopenia: a systematic review

.

Pediatr Blood Cancer

.

2023

;

70

(

3

):

e30173

.

73.

Russo

G

,

Parodi

E

,

Farruggia

P

, et al.

Recommendations for the management of acute immune thrombocytopenia in children. A Consensus Conference from the Italian Association of Pediatric Hematology and Oncology

.

Blood Transfus

.

2024

;

22

(

3

):

253

-

265

.

74.

Nikitin

E

,

Kislova

M

,

Morozov

D

, et al.

Ibrutinib in combination with rituximab is highly effective in treatment of chronic lymphocytic leukemia patients with steroid refractory and relapsed autoimmune cytopenias

.

Leukemia

.

2023

;

37

(

7

):

1464

-

1473

.

75.

Atschekzei

F

,

Traidl

S

,

Carlens

J

, et al.

JAK inhibitors to treat STAT3 gain-of-function: a single-center report and literature review

.

Front Immunol

.

2024

;

15

:

1400348

.